R. Ueda

Publications704
h-index89
Citations27,696
Highly Influential Citations891
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • T. Ishida
  • 183 Publications • 5,794 Citations
  • S. Iida
  • 432 Publications • 9,075 Citations
  • A. Utsunomiya
  • 423 Publications • 11,781 Citations
  • M. Mizokami
  • 841 Publications • 38,067 Citations
  • Publications
  • Influence
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
TLDR
The FLT3 gene mutation, whose presence is detectable only by genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML.
Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.
TLDR
Investigation of immunostaining analysis for CCR4 and CXCR3 expression in ATLL cells obtained from 103 patients with ATLL revealed a novel insight into not only the biological but also the clinical features of ATLL, and multivariate analysis confirmed that C CR4 expression was an independent and significant prognostic factor.
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
TLDR
It is suggested that CD5+DLBCL may constitute a unique subgroup of DLBCL, and this subgroup was characterized by a survival curve significantly inferior to that for patients with CD5- DL BCL.
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
TLDR
The results suggest that the N PM1 mutation is not necessarily an early event during leukemogenesis or that leukemia clones with NPM1 mutations are sensitive to chemotherapy.
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
TLDR
KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL, and subsequent phase II studies at the 1.0 mg/kg dose are thus warranted.
Hepatitis B Virus of Genotype B with or without Recombination with Genotype C over the Precore Region plus the Core Gene
TLDR
Two subgroups of HBV/B were identified based on sequence divergence in the precore region plus the core gene, one with the recombination with genotype C and the other without it, which seems to be under strong geographic influences in Asia.
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.
TLDR
Results show that the Asn505 is an activating mutation with respect to the intracellular signaling and survival of the cells, the first report of FET deriving from a dominant-positive activating mutation of the c-MPL gene.
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
  • T. Ishida, T. Joh, R. Ueda
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 10 March 2012
TLDR
KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile, and further investigation of KW-761 for treatment of ATL and other T-cell neoplasms is warranted.
Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
TLDR
Whether the antitumor activity of KW-0761 would likely be sufficient for therapeutic clinical application against ATLL and the mechanism of antibody-dependent cellular cytotoxicity mediated by this defucosylated monoclonal antibody is investigated.
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
  • M. Ogura, T. Ishida, R. Ueda
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 10 April 2014
TLDR
Mogamulizumab exhibited clinically meaningful antitumor activity in patients with relapsed PTCL and CTCL, with an acceptable toxicity profile, and further investigation of mogamulIZumab for treatment of T-cell lymphoma is warranted.
...
1
2
3
4
5
...